ATG16L1 and neoplasm: Taken together, we conclude that in non-MSI CRC, patients with ATG16L1-low tumors may generate a more inflammatory microenvironment, thereby promoting a productive anti-tumor immune response upon checkpoint inhibition with atezolizumab.